BioSpace News Archive

Caris Life Sciences today announced a strategic research partnership with Incyte Corporation (NASDAQ:INCY) to augment precision medicine approaches for Incyte’s oncology pipeline.

Monopar Therapeutics Inc. announced that Chandler Robinson, MD, Monopar’s Chief Executive Officer, will participate in a fireside chat at the 35th Annual Roth Conference.

Virios Therapeutics, Inc. (Nasdaq: VIRI) announced today that it will report fourth quarter and full year 2022 financial results on Tuesday, March 14, 2023 before the open of the financial markets.

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that preclinical results of mTNX-1700 (recombinant murine TFF2-murine serum albumin, or MSA, fusion protein) were presented in a poster at the Keystone Symposia, “Cancer Immunotherapy: Mechanisms of Response Versus Resistance” on March 6, 2023, at the Fairmont Banff Springs Conference Center in Banff, Alberta, Canada.

Augmedix Inc. (Nasdaq: AUGX) today announced that Manny Krakaris, Chief Executive Officer, and Paul Ginocchio, Chief Financial Officer will attend and present at the Oppenheimer 33rd Annual Healthcare Conference taking place virtually on March 13 – 15, 2023.

Avalo Therapeutics, Inc. announced that Garry A. Neil, M.D., President and Chief Executive Officer, will present virtually at Oppenheimer’s 33rd Annual Healthcare Conference on Monday, March 13, 2023 at 1:20 p.m. ET.

Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the fourth quarter and year ended December 31, 2022.

GreenLight Biosciences will outline its pipeline strategy and R&D progress for dsRNA based crop protection and plant delivery innovations focused on addressing food security with innovative and sustainable solutions during its Plant Health R&D Day being held today, March 7th, 2023 at 10:30 a.m. ET in Research Triangle, North Carolina.

Exscientia plc (Nasdaq: EXAI) today announced a new collaboration with Charité – Universitätsmedizin Berlin (Charité) to utilise Exscientia’s AI-driven precision medicine platform in haematological cancers.

Rapport Therapeutics, Inc., a clinical-stage biotechnology company dedicated to the discovery and development of precision medicines for neurological disorders, launched with a $100 million Series A financing from Third Rock Ventures, ARCH Venture Partners and Johnson & Johnson Innovation – JJDC, Inc.